Summary of Clinical Trial Findings
Study Focus
This study investigated how well oral supplements of magnesium and vitamin D can reduce mild to moderate depression symptoms in people suffering from long-COVID.
Key Outcomes
- Participants: 60 individuals aged around 53 years with low magnesium and vitamin D levels, along with mild to moderate depression.
- Method: Participants were divided into two groups: one group received magnesium (1300 mg) and vitamin D (4000 IU), while the other group received only vitamin D for four months.
- Results:
- Significant improvement in depression symptoms was noted in those taking both supplements, with scores improving from an average of 28.8 to 9.2.
- 73.2% of the intervention group showed a marked reduction in depressive symptoms, reaching scores considered normal, compared to 34.5% in the control group.
- Safety: Mild side effects were noted but did not require stopping the treatment.
Practical Solutions and Value
This trial highlights that combining magnesium and vitamin D can effectively improve mental health in individuals with long-COVID. This information can guide healthcare providers in recommending these supplements for symptomatic relief.
Optimizing Clinical Practice
Using the right tools is crucial in healthcare. Our AI platform, DocSym, integrates clinical guidelines and research into a user-friendly resource for healthcare professionals.
Enhancing Patient Care
Our mobile applications simplify scheduling, treatment tracking, and telemedicine, improving patient management and access to services.
Explore how we can assist in enhancing your clinic’s efficiency and patient outcomes at aidevmd.com.
